Amedisys (AMED) reported $621.86 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 5.2%. EPS of $1.54 for the same period compares to $1.32 a year ago.
The reported revenue represents a surprise of +2% over the Zacks Consensus Estimate of $609.65 million. With the consensus EPS estimate being $1.39, the EPS surprise was +10.79%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Amedisys performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Service Revenue- High Acuity Care: $10.7 million versus $10.38 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.2% change.
- Net Service Revenue- Hospice: $215 million versus the three-analyst average estimate of $210.75 million. The reported number represents a year-over-year change of +5.4%.
- Net Service Revenue- Home health: $396.2 million versus the three-analyst average estimate of $386.85 million. The reported number represents a year-over-year change of +5%.
View all Key Company Metrics for Amedisys here>>>
Shares of Amedisys have returned -1.5% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amedisys, Inc. (AMED): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
